| MeSH term | MeSH ID | Detail |
|---|---|---|
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Asthma | D001249 | 52 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Thrombosis | D013927 | 49 associated lipids |
| Cerebral Hemorrhage | D002543 | 13 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Cerebrovascular Disorders | D002561 | 25 associated lipids |
| Polycythemia Vera | D011087 | 13 associated lipids |
| Hyperlipidemias | D006949 | 73 associated lipids |
| Blood Platelet Disorders | D001791 | 12 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Renal Artery Obstruction | D012078 | 8 associated lipids |
| Atrial Fibrillation | D001281 | 16 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
| Death, Sudden, Cardiac | D016757 | 12 associated lipids |
| Hypoalphalipoproteinemias | D052456 | 5 associated lipids |
11-dehydro-txb2
Cross Reference
Introduction
To understand associated biological information of 11-dehydro-txb2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 11-dehydro-txb2?
11-dehydro-txb2 is suspected in Risk factor, cardiovascular, Acute coronary syndrome, thrombocytosis, Chronic ischemic heart disease NOS, Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-Dependent and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 11-dehydro-txb2
PubChem Associated disorders and diseases
What pathways are associated with 11-dehydro-txb2
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What functions are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
What genes are associated with 11-dehydro-txb2?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 11-dehydro-txb2?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with 11-dehydro-txb2
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Carroll RC et al. | A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane. | 2013 | Anesth. Analg. | pmid:23302970 |
| Foulon I et al. | Increased in vivo production of thromboxane in patients with sickle cell disease is accompanied by an impairment of platelet functions to the thromboxane A2 agonist U46619. | 1993 | Arterioscler. Thromb. | pmid:8443146 |
| Bröijersén A et al. | No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9081681 |
| Davi G et al. | In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. | 1997 | Arterioscler. Thromb. Vasc. Biol. | pmid:9409316 |
| Davì G et al. | Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. | 2005 | Arterioscler. Thromb. Vasc. Biol. | pmid:15472127 |
| Stein CM et al. | Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. | 1996 | Arthritis Rheum. | pmid:8670323 |
| Cracowski JL et al. | Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders. | 2001 | Arthritis Rheum. | pmid:11352247 |
| Ferro D et al. | Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. | 1999 | Arthritis Rheum. | pmid:10616019 |
| Jörres A et al. | Urinary excretion of thromboxane and markers for renal injury in patients undergoing cardiopulmonary bypass. | 1994 | Artif Organs | pmid:7527629 |
| Takayama K et al. | Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. | 1991 Jul-Sep | ASAIO Trans | pmid:1836334 |
| Falco A et al. | Inhibition of thromboxane biosynthesis by triflusal in type 2 diabetes mellitus. | 2005 | Atherosclerosis | pmid:16285996 |
| Markuszewski L et al. | Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin? | 2006 | Basic Clin. Pharmacol. Toxicol. | pmid:16635110 |
| Calapai G et al. | Cardiovascular biomarkers in groups of established smokers after a decade of smoking. | 2009 | Basic Clin. Pharmacol. Toxicol. | pmid:19175368 |
| Liu TF et al. | [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease]. | 2015 | Beijing Da Xue Xue Bao | pmid:26679651 |
| Varma D et al. | Comparison of UHPLC and HPLC methods for the assay of prostanoids: "are the methods equivalent in terms of accuracy and precision?". | 2011 | Bioanalysis | pmid:21510759 |
| Ciabattoni G et al. | Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. | 1989 | Biochim. Biophys. Acta | pmid:2752040 |
| Patrignani P et al. | Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. | 1989 | Biochim. Biophys. Acta | pmid:2752041 |
| Wu P et al. | Purification and characterization of an NAD(+)-dependent dehydrogenase that catalyzes the oxidation of thromboxane B2 at C-11 from porcine liver. Development and application of 11-dehydro-thromboxane B2 radioimmunoassay to enzyme assay. | 1990 | Biochim. Biophys. Acta | pmid:2223826 |
| Lorenz RL et al. | A critical evaluation of urinary immunoreactive thromboxane: feasibility of its determination as a potential vascular risk indicator. | 1989 | Biochim. Biophys. Acta | pmid:2597697 |
| Ciabattoni G et al. | Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. | 1987 | Biochim. Biophys. Acta | pmid:3567215 |